YCT529 CAS: YCT-529

CAS NO: YCT-529
YCT529
Description Review
Description

Modern-day science has brought unique compounds, chemicals, and substances to humanity, each promising a range of health benefits. One such remarkable discovery is YCT529. This exceptional compound has shown much potential in enhancing overall health, including memory and cognitive ability. In this article, we will provide comprehensive information regarding YCT529.

What Is YCT529?

YCT529 is a small molecule that belongs to the fenamate chemical family, which is structurally similar to other fenamate-based molecules, such as mefenamic acid and flufenamic acid. Its development primarily focused on its therapeutic potential for treating neurological conditions, such as Alzheimer’s disease, Huntington’s disease, and epilepsy.

Chemical Name

The chemical name of YCT529 is 2-(2-(4-bromophenyl) phenyl) propanoic acid.

Molecular Formula

The molecular formula of YCT529 is C15H13BrO2.

Formula Weight

The formula weight of YCT529 is 319.17 g/mol.

CAS No

YCT529's CAS number is 1052134-14-0.

Top Ten Keywords from Google and Synonyms

  1. YCT529 hydrobromide
  2. Alzheimer's drug development
  3. Fenamate compounds
  4. Cognitive enhancer
  5. Neuroprotective agent
  6. Br-phenyl-propanoic acid
  7. Huntington's disease treatment
  8. YCT529 structure
  9. Preclinical studies
  10. Anti-seizure drug development

The Health Benefits of YCT529

Studies suggest that YCT529 may have several health benefits, especially in enhancing cognitive ability and reducing symptoms of neurological conditions. One of the primary mechanisms behind this is the drug's impact on brain inflammation. Chronic inflammation in the brain plays a significant role in the development of many neurological disorders.

YCT529 contains anti-inflammatory properties that inhibit the production of pro-inflammatory cytokines, effectively reducing inflammation in the brain. This helps protect the neurons and other crucial brain cells, enhancing overall brain function.

According to preclinical studies, YCT529 can offer the following potential effects to the body:

  1. Cognitive enhancement: The drug may improve cognitive function by enabling better memory consolidation, learning, and information processing speed.

  2. Neuroprotection: YCT529 contains neuroprotective properties that protect neurons and other vital brain cells from damage.

  3. Alzheimer's treatment: Research using animal models suggests that YCT529 may be a promising therapeutic agent for Alzheimer's disease. The drug has demonstrated the ability to inhibit the formation of amyloid-beta peptides that play a crucial role in the disease's development.

Product Mechanism

YCT529 is a potent modulator of the brain's N-methyl-D-aspartate (NMDA) receptors, which regulate brain activity by modulating the neurotransmitter glutamate. These receptors play an essential role in neuronal communication, including the formation of new memories.

By regulating NMDA receptors, YCT529 reduces inflammation and protects the neurons, which can lead to better cognitive function.

Safety

Preclinical studies have shown that YCT529 is relatively safe for use, with no significant adverse effects reported. Moreover, the drug has not shown any signs of toxicity or damage to critical organs, such as the liver or kidneys.

Side Effects

While YCT529 has not demonstrated any significant adverse effects in preclinical studies, potential side effects such as headaches, dizziness, and gastrointestinal problems are possible. These side effects are similar to those associated with other non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code